


**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

1. **(Currently Amended)** A compound of formula (I)



wherein ring A represents a benzene ring which may have a substituent(s), wherein the substituent(s) is 1 to 5 optional substituent(s) selected from the group of methyl, ethyl, a fluorine atom, a chlorine atom, methoxy, ethoxy, difluoromethoxy, hydroxyl, and acetyl, trifluoromethoxy, methylsulfonyl, acetylarnino, methylsulfonylarnino, 1-hydroxy-1-methylethyl, 1-propenyl and cyano;

ring B represents a benzene ring which may have a substituent(s), a thiophene ring which may have a substituent(s), an indan ring which may have a substituent(s), or a 1,3-benzodioxole ring which may have a substituent(s), or a cyclopentane ring which may have a substituent(s), wherein the substituent(s) is 1 to 5 optional substituent(s) selected from the group consisting of methyl, ethyl, propyl, a fluorine atom, and a chlorine atom, methoxy and ethoxy;

K represents C1-4 alkylene which may be substituted with 1 to 5 optional substituent(s) selected from the group consisting of methyl, a fluorine atom, hydroxy, and oxo;

Q represents methylene, or ethylene,  $\text{O}$ , or  $\text{CH}_2\text{O}$ ;

M represents a bond, C1-4 alkylene which may have a substituent(s), or C2-4 alkenylene which may have a substituent(s), wherein the substituent(s) is 1 to 5 optional substituent(s) selected from the group consisting of methyl and hydroxyl;

ring D represents a benzene ring which may have a substituent(s), a pyrrole ring which may have a substituent(s), an imidazole ring which may have a substituent(s), a pyrazole ring which may have a substituent(s), an oxazole ring which may have a substituent(s), or a thiazole ring which may have a substituent(s), or a thiophene ring which may have a substituent(s), wherein the substituent(s) is 1 to 5 optional substituent(s) selected from the group consisting of carboxy, methyl, a fluorine atom, a chlorine atom, and methoxycarbonyl, ethoxycarbonyl, aminocarbonyl, N-methylaminocarbonyl, N,N-dimethylaminocarbonyl, and acetyl;

ring E represents a benzene ring which may have a substituent(s), wherein the substituent(s) is 1 to 5 optional substituent(s) selected from the group consisting of methyl, a chlorine atom, a fluorine atom, methoxy, and ethoxy;

L represents a bond, or  $\text{CH}_2$ ,  $\text{O}$ ,  $\text{S}$ ,  $\text{SO}$ ,  $\text{SO}_2$  or  $\text{NH}$ ;


Z represents  $\text{COOH}$ ,  $\text{CONHSO}_2\text{R}^1$ , in which  $\text{R}^1$  represents methyl, or C1-8 alkyl which may be substituted, a benzene ring which may have a substituent(s), a pyridine ring which may have a substituent(s), a thiophene ring which may have a substituent(s), a furan ring which may have a substituent(s), a imidazole ring which may have a substituent(s), a thiazole ring which may have a substituent(s), an isoxazole ring which may have a substituent(s), a morpholine ring which may have a substituent(s), wherein the substituent(s) is 1 to 5 optional substituent(s)

selected from the group consisting of methyl, ~~tert~~ butyl, a chlorine atom, a fluorine atom, trifluoromethyl, methoxy, trifluoromethoxy, and acetyl; and

$t$  represents 0 or 1, or

a salt thereof, ~~or a solvate thereof~~.

2. **(Original)** The compound according to claim 1, wherein the compound of formula (I) is an optically active compound of formula (I-A):



wherein represents  $\beta$ -configuration; and other symbols have the same meanings as described in claim 1.

3.-4. **(Canceled)**


5. **(Previously presented)** The compound according to claim 1, wherein ring B is an indan ring which may have a substituent(s).

6. **(Canceled)**

7. **(Original)** The compound according to claim 1, wherein ring D is a benzene ring which may have a substituent(s), a pyrazole ring which may have a substituent(s) or a pyrrole ring which may have a substituent(s).


8. **(Canceled)**

9. **(Original)** The compound according to claim 1, wherein



is methylene which may be substituted, ethylene which may be substituted, propylene which may be substituted, or ethenylene which may be substituted.

10. **(Currently Amended)** The compound according to claim 1, wherein ring A is a benzene ring which may have a substituent(s); ring B is an indan ring which may have a substituent(s); ring D is a benzene ring which may have a substituent(s), a pyrazole ring which may have a substituent(s) or a pyrrole ring which may have a substituent(s);



is methylene which may be substituted, ethylene which may be substituted, propylene which may be substituted, or ethenylene which may be substituted; and

Z is -COOH; -CONHSO<sub>2</sub>R<sup>1</sup>, in which R<sup>1</sup> is methyl-C1-8 alkyl which may be substituted, a benzene ring which may have a substituent(s).

11. (Original) The compound according to claim 1, which is selected from the group consisting of:

- (1) {1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}acetic acid,
- (2) (1-[(2S)-2-[(S)-(3,5-dimethoxy-4-methylphenyl)(hydroxy)methyl]-5-thien-3-ylpentyl]-1H-pyrrol-3-yl)acetic acid,
- (3) {1-[(2S,3S)-2-(1,3-benzodioxol-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}acetic acid,
- (4) {1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-hydroxy-3-(3,4,5-trimethoxyphenyl)propyl]-1H-pyrrol-3-yl}acetic acid,
- (5) {1-[(2S,3S)-3-(4-acetyl-3,5-dimethoxyphenyl)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}acetic acid,
- (6) {1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(4-ethyl-3,5-dimethoxyphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}acetic acid,
- (7) 3-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}propanoic acid,

(8) 3-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-hydroxy-3-(3,4,5-trimethoxyphenyl)propyl]-1H-pyrrol-3-yl}propanoic acid,

(9) 3-{1-[(2S,3S)-3-(4-acetyl-3,5-dimethoxyphenyl)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}propanoic acid,

(10) 3-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(4-ethyl-3,5-dimethoxyphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}propanoic acid,

(11) 2-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}-N-(methylsulfonyl)acetamide,

(12) [1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxylpropyl]-4-(methoxylcarbonyl)-1H-pyrrol-3-yl]acetic acid,

(13) N-(3-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}propanoyl)-2-methylbenzenesulfonamide,

(14) (2E)-3-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}acrylic acid,

(15) 2-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}-2-methylpropanoic acid, and

(16) (2E)-3-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}-2-methylacrylic acid.

12. **(Previously presented)** A pharmaceutical composition comprising the compound of formula (I) according to claim 1, or a salt thereof, ~~or~~ a solvate thereof.

13. **(Original)** The pharmaceutical composition according to claim 12, which is an LPA receptor antagonist, wherein the LPA receptor is EDG-2.

14. **(Canceled)**

15. **(Original)** The pharmaceutical composition according to claim 12, which is an agent for prevention and/or treatment for urinary system disease.

16. **(Currently Amended)** A method for treatment of urinary system disease selected from the group of prostatic hypertrophy, neurogenic bladder dysfunction disease, dysuria, pollakiuria, night urination and urodynia, which comprises administering to a mammal an effective amount of the compound of formula (I) according to claim 1, or a salt thereof, ~~or~~ a solvate thereof.

17. **(Canceled)**

18. **(Currently Amended)** A pharmaceutical composition comprising a combination of the compound of formula (I) according to claim 1, or a salt thereof, ~~a~~ solvate thereof with at least one agent selected from an LPA receptor antagonist, an  $\alpha$ 1 blocking agent, an anticholinergic agent, a 5 $\alpha$ -reductase inhibitor and an anti-androgenic agent.